Advertisement

Pharmaceutical Chemistry Journal

, Volume 46, Issue 1, pp 15–19 | Cite as

Synthesis and antidepressant and anxiolytic activity of derivatives of pyrazolo[4,3-c]pyridine and 4-phenylhydrazinonicotinic acids

  • L. A. Zhmurenko
  • G. M. Molodavkin
  • T. A. Voronina
  • V. P. Lezina
Article

The synthesis of compounds effective in the treatment of anxiety—depression disorders is described. It is established that 4,6-dimethyl-2-(4-chlorophenyl)-2,3-dihydro-1H-pyrazolo[4,3-c]pyridine-3-one hydrochloride (IVa) possesses combined antidepressant and anxiolytic properties. Advantages of IVa are low toxicity and the absence of side effects typical of antidepressants (elevated anxiety) and benzodiazepine anxiolytics (myorelaxant and sedative action).

Key words

synthesis of pyrazolo[4,3-c]pyridine-3-ones synthesis of 4-phenylhydrazinonicotinic acid derivatives antidepressant activity anxiolytic activity 

References

  1. 1.
    M. S. Allen, P. Skolnick, and J. M. Cook, J. Med. Chem., 35, 368–374 (1992).PubMedCrossRefGoogle Scholar
  2. 2.
    I. T. Forbes, C. N. Johnson, G. E. Jones, et al., J. Med. Chem., 33, 2640–2645 (1990).PubMedCrossRefGoogle Scholar
  3. 3.
    N. Yokoyama, B. Ritter, and A. D. Neubert, J. Med. Chem., 25, 337–339 (1982).PubMedCrossRefGoogle Scholar
  4. 4.
    O. M. Glozman, L. A. Zhmurenko, V. P. Lezina, et al., Khim.-farm. Zh., 35(11), 8–10 (2001).Google Scholar
  5. 5.
    A. Michaelis, Liebigs Ann. Chem., 366, 324–407 (1909).CrossRefGoogle Scholar
  6. 6.
    N. I. Andreeva, Handbook of Experimental (Preclinical) Study of New Drugs [in Russian], R. U. Khabriev (ed.), Meditsina, Moscow (2005), pp. 244–252.Google Scholar
  7. 7.
    R. D. Porsolt, et al., Eur. J. Pharmacol., 47, 379–391 (1978).PubMedCrossRefGoogle Scholar
  8. 8.
    S. Nomura, J. Shimizu, M. Kinjo, et al., Eur. J. Pharmacol., 83, 171–175 (1982).PubMedCrossRefGoogle Scholar
  9. 9.
    G. M. Molodavkin, T. A. Voronina, and A. L. Mdzinarishvili, Eksp. Klin. Farmakol., 57(1), 3–5 (1994).PubMedGoogle Scholar
  10. 10.
    T. A. Voronina and S. B. Seredenin, Handbook of Experimental (Preclinical) Study of New Drugs [in Russian], R. U. Khabriev (ed.), Meditsina, Moscow (2005), pp. 253–262.Google Scholar
  11. 11.
    G. M. Molodavkin and T. A. Voronina, Eksp. Klin. Farmakol., 58(2), 54–56 (1995).PubMedGoogle Scholar
  12. 12.
    E. V. Arzamastsev, T. A. Gus’kova, I. V. Berezovskaya, et al., Handbook of Experimental (Preclinical) Study of New Drugs [in Russian], R. U. Khabriev (ed.), Meditsina, Moscow (2005), pp. 41–53.Google Scholar

Copyright information

© Springer Science+Business Media, Inc. 2012

Authors and Affiliations

  • L. A. Zhmurenko
    • 1
  • G. M. Molodavkin
    • 1
  • T. A. Voronina
    • 1
  • V. P. Lezina
    • 1
  1. 1.Zakusov Institute of PharmacologyRussian Academy of Medical SciencesMoscowRussia

Personalised recommendations